Dilon Technologies
Newport News, US · Delaware corporation
Dilon Technologies develops, manufactures, and markets medical devices for women's healthcare and biosurgery, including breast cancer margin assessment (MarginProbe), surgical hemostats, radio-guided surgery systems, and video laryngoscopes. Its products are sold to healthcare providers and surgeons.
Founders & leadership
TJ
Tim JetteExecutive
GM
George MakhoulExecutive
RG
Robert G. MoussaExecutive
VS
Vijay SinghExecutive
PL
Pjerin LuliExecutive
MW
Michael W. TillerExecutive
BW
Benjamin WelchExecutive
Board
MN
Michael N. TaglichBoard director
RT
Robert TaglichBoard director
MH
Mark H. RavichBoard director
RF
Rachel F. BremBoard director
FB
Francis BissaillonBoard director
Reported raises · per SEC filings
Form D private placements$45.7M disclosed across 6 rounds · 2017–2025
▶$8.1MraisedMar 2026 · 184 investors · BiotechnologyRule 506(b)
▶$8.1MraisedMar 2026 · 184 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. MoussaDirector
- Rachel F. BremDirector
- Robert TaglichDirector
- Francis BissaillonDirector
- Michael N. TaglichDirector
- Tim JetteExecutive Officer
- George MakhoulExecutive Officer, Director
- Offering amount
- $10.4M
- Amount sold
- $8.1M
- Minimum investment
- $5K
- Sales commissions
- $644.5K
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.1MraisedJan 2025 · 148 investors · BiotechnologyRule 506(b)
▶$21.1MraisedJan 2025 · 148 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tim JetteExecutive Officer
- Michael N. TaglichDirector
- Rachel F. BremDirector
- George MakhoulExecutive Officer, Director
- Robert G. MoussaExecutive Officer, Director
- Robert TaglichDirector
- Francis BissaillonDirector
- Offering amount
- $30M
- Amount sold
- $21.1M
- Minimum investment
- $10K
- Sales commissions
- $1.7M
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedApr 2023 · 17 investors · BiotechnologyRule 506(b)
▶$2.7MraisedApr 2023 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Francis BissaillonDirector
- George N. MakhoulExecutive Officer, Director
- Michael N. TaglichDirector
- Rachel F. BremDirector
- Robert G. MoussaExecutive Officer, Director
- Michael W. TillerExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $2.7M
- Minimum investment
- $10K
- Sales commissions
- $218.2K
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.6MraisedOct 2022 · 39 investors · BiotechnologyRule 506(b)
▶$4.6MraisedOct 2022 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael W. TillerExecutive Officer
- Rachel F. BremDirector
- George N. MakhoulExecutive Officer, Director
- Mark H. RavichDirector
- Francis BissaillonDirector
- Robert G. MoussaExecutive Officer, Director
- Michael N. TaglichDirector
- Offering amount
- $8M
- Amount sold
- $4.6M
- Minimum investment
- $10K
- Sales commissions
- $289.2K
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedFeb 2022 · 49 investors · BiotechnologyRule 506(b)
▶$4.1MraisedFeb 2022 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. MoussaExecutive Officer, Director
- Michael W. TillerExecutive Officer
- Mark H. RavichDirector
- Rachel F. BremDirector
- Michael N. TaglichDirector
- Offering amount
- $10M
- Amount sold
- $4.1M
- Minimum investment
- $10K
- Sales commissions
- $343.2K
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedFeb 2018 · 81 investors · BiotechnologyRule 506(b)
▶$5.1MraisedFeb 2018 · 81 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vijay SinghExecutive Officer
- Michael N. TaglichDirector
- Mark H. RavichDirector
- Pjerin LuliExecutive Officer
- Michael W. TillerExecutive Officer
- Robert G. MoussaExecutive Officer, Director
- Benjamin WelchExecutive Officer
- Rachel F. BremDirector
- Offering amount
- $5.5M
- Amount sold
- $5.1M
- Minimum investment
- $5K
- Sales commissions
- $315.6K
- Placement agents
- Taglich Brothers, Inc., Taglich Brothers, Inc., Taglich Brothers, Inc.
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Doximity27 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Cancerresearchuk25 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer Center24 shared keywordsUT MD Anderson is a cancer hospital providing cancer treatment, prevention, clinical care, and research, including new therapies and clinical trials for cancer patients. It is ranked among the top hospitals in the U.S. for cancer care.
Companies competing with Dilon Technologies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Dilon Technologies do?
- Dilon Technologies develops, manufactures, and markets medical devices for women's healthcare and biosurgery, including breast cancer margin assessment (MarginProbe), surgical hemostats, radio-guided surgery systems, and video laryngoscopes. Its products are sold to healthcare providers and surgeons.
- How much funding has Dilon Technologies raised?
- Dilon Technologies has disclosed $45.7M raised across 6 rounds.
- Where is Dilon Technologies headquartered?
- Dilon Technologies is headquartered in Newport News, US.